Galectin Therapeutics Inc (GALT)

0.8702 +0.03 (+3.52%) USD  |  NASDAQ  |  Dec 26, 16:00
0.8702 0.00 (0.00%) After-Hours: 18:05
More

Galectin Therapeutics Research and Development Expense (Quarterly): 7.595M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for GALT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Alaunos Therapeutics Inc 0.143M
SELLAS Life Sciences Group Inc 4.362M
Oragenics Inc 0.879M
Anavex Life Sciences Corp 11.56M
Phathom Pharmaceuticals Inc 8.693M